| 1. |
Asanoma K, Yagi H, Onoyama I, Cui L, Hori E, Kawakami M, Maenohara S, Hachisuga K, Tomonobe H, Kodama K, Yasunaga M, Ohgami T, Okugawa K, Yahata H, Kitao H, Kato K., The BHLHE40‒PPM1F‒AMPK pathway regulates energy metabolism and is associated with the aggressiveness of endometrial cancer, J Biol Chem, 10.1016/j.jbc.2024.105695, 300, 3, 105695, 2024.03. |
| 2. |
Hachisuga K, Kawakami M, Tomonobe H, Maenohara S, Kodama K, Yagi H, Yasunaga M, Onoyama I, Asanoma K, Yahata H, Oda Y, Kato K., Clinical Significance of Tumor Immune Microenvironment in Endometrial Endometrioid Carcinoma, Grade 1 With DNA Mismatch Repair Protein Loss., Int J Gynecol Pathol, 10.1097/PGP.0000000000001020., 2024.01. |
| 3. |
Kodama K, Tateishi C, Oda T, Cui L, Kuramoto K, Yahata H, Okugawa K, Maenohara S, Yagi H, Yasunaga M, Onoyama I, Asanoma K, Mori T, Katayama Y, Kato K., Development of novel tracers for sentinel node identification in cervical cancer., Cancer Sci, 10.1111/cas.15927., 114, 11, 4216, 2023.11. |
| 4. |
Kodama K, Tateishi C, Oda T, Cui L, Kuramoto K, Yahata H, Okugawa K, Maenohara S, Yagi H, Yasunaga M, Onoyama I, Asanoma K, Mori T, Katayama Y, Kato K., Decision-making for Subsequent Therapy for Patients With Recurrent or Advanced Endometrial Cancer Based on the Platinum-free Interval., Am J Clin Oncol., 10.1097/COC.0000000000001021., 46, 9, 387, 2023.09. |
| 5. |
Yagi H, Onoyama I, Asanoma K, Kawakami M, Maenohara S, Kodama K, Matsumura Y, Hamada N, Hori E, Hachisuga K, Yasunaga M, Ohgami T, Okugawa K, Yahata H, Kato K., Tumor-derived ARHGAP35 mutations enhance the Gα13-Rho signaling axis in human endometrial cancer., Cancer Gene Ther, 10.1038/s41417-022-00547-1., 30, 2, 313, 2023.02. |
| 6. |
Yasunaga M, Yahata H, Okugawa K, Shimokawa M, Maeda Y, Hori E, Kodama K, Yagi H, Ohgami T, Onoyama I, Asanoma K, Kato K., Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer., Taiwan J Obstet Gynecol., 10.1016/j.tjog.2022.06.005., 61, 5, 818, 2022.09. |
| 7. |
Yahata H, Kodama K, Okugawa K, Hachisuga K, Yasutake N, Maenohara S, Yagi H, Yasunaga M, Ohgami T, Onoyama I, Asanoma K, Kobayashi H, Sonoda K, Baba S, Ishigami K, Ohishi Y, Oda Y, Kato K., Long-term follow up after sentinel node biopsy alone for early-stage cervical cancer., Gynecol Oncol, 10.1016/j.ygyno.2022.01.031., 165, 1, 149, 2022.04. |
| 8. |
Okugawa K, Yahata H, Hachisuga K, Tomonobe H, Yasutake N, Kodama K, Kenjo H, Yagi H, Ohgami T, Yasunaga M, Onoyama I, Asanoma K, Hori E, Ohishi Y, Oda Y, Kato K, Evaluation of Clinical Significance of Lymphovascular Space Invasion in Stage IA Endometrial Cancer., Oncology, 10.1159/000521382., 100, 4, 195, 2021.12. |
| 9. |
Yasunaga M, Yahata H, Okugawa K, Hori E, Kodama K, Yagi H, Ohgami T, Onoyama I, Asanoma K, Kato K., Prognostic impact of the subclassification of Müllerian cancer stage IV in the FIGO 2014 staging system with a focus of extra-abdominal lymph node metastases., Int J Clin Oncol., 10.1007/s10147-021-01908-w., 26, 7, 1330, 2021.07. |
| 10. |
Yamaguchi S, Yahata H, Okugawa K, Kodama K, Yagi H, Yasunaga M, Ohgami T, Onoyama I, Asanoma K, Kato K., Hypersensitivity reaction to pegylated liposomal doxorubicin administration for Mullerian carcinoma in Japanese women., J Obstet Gynaecol Res., 10.1111/jog.14680., 47, 4, 1544, 2021.04. |
| 11. |
Kodama K, Yahata H, Okugawa K, Tomonobe H, Yasutake N, Yoshida S, Yagi H, Yasunaga M, Ohgami T, Onoyama I, Asanoma K, Hori E, Shimokawa M, Kato K., Prognostic outcomes and risk factors for recurrence after laser vaporization for cervical intraepithelial neoplasia: a single-center retrospective study. , Int J Clin Oncol. , 10.1007/s10147-020-01848-x., 26, 4, 770, 2021.04. |
| 12. |
Yoshida S, Asanoma K, Yagi H, Onoyama I, Hori E, Matsumura Y, Okugawa K, Yahata H, Kato K, Fibronectin mediates activation of stromal fibroblasts by SPARC in endometrial cancer cells, BMC Cancer, 21, 1, 1-12, 2021.02. |
| 13. |
Suzuki I, Yoshida S, Tabu K, Kusunoki S, Matsumura Y, Izumi H, Asanoma K, Yagi H, Onoyama I, Sonoda K, Kohno K, Taga T, Itakura A, Takeda S, Kato K., YBX2 and cancer testis antigen 45 contribute to stemness, chemoresistance and a high degree of malignancy in human endometrial cancer., Sci Rep, 10.1038/s41598-021-83200-5., 11, 1, 4220, 2021.02. |
| 14. |
Kawamura T, Tomari H, Onoyama I, Araki H, Yasunaga M, Lin C, Kawamura K, Yokota N, Yoshida S, Yagi H, Asanoma K, Sonoda K, Egashira K, Ito T, Kato K., Identification of genes associated with endometrial cell ageing. , Mol Hum Reprod, 10.1093/molehr/gaaa078., 27, 2, 2021.02. |
| 15. |
Okugawa K, Yahata H, Sonoda K, Kodama K, Yagi H, Ohgami T, Yasunaga M, Onoyama I, Kaneki E, Asanoma K, Kobayashi H, Kato K., Evaluation of adjuvant chemotherapy after abdominal trachelectomy for cervical cancer: a single-institution experience. , Int J Clin Oncol., 10.1007/s10147-020-01778-8., 26, 1, 216, 2021.01. |
| 16. |
Kato M, Onoyama I, Kawakami M, Yoshida S, Kawamura K, Kodama K, Hori E, Cui L, Matsumura Y, Yagi H, Asanoma K, Yahata H, Itakura A, Takeda S, Kato K., Downregulation of 5-hydroxymethylcytosine is associated with the progression of cervical intraepithelial neoplasia. , PLoS One, 10.1371/journal.pone.0241482., 15, 11, 2020.11. |
| 17. |
Kato M, Onoyama I, Yoshida S, Cui L, Kawamura K, Kodama K, Hori E, Matsumura Y, Yagi H, Asanoma K, Yahata H, Itakura A, Takeda S, Kato K., Dual-specificity phosphatase 6 plays a critical role in the maintenance of a cancer stem-like cell phenotype in human endometrial cancer. , Int J Cancer, 10.1002/ijc.32965., 147, 7, 1987, 2020.10. |
| 18. |
17. Yahata H, Sonoda K, Inoue S, Yasutake N, Kodama K, Yagi H, Yasunaga M, Ohgami T, Onoyama I, Kaneki E, Okugawa K, Asanoma K, Kato K., Is Adjuvant Therapy Necessary for Patients with Intermediate-Risk Cervical Cancer after Open Radical Hysterectomy? , Oncology., 10.1159/000508569., 98, 12, 853, 2020.07. |
| 19. |
Yagi H, Onoyama I, Asanoma K, Hori E, Yasunaga M, Kodama K, Kijima M, Ohgami T, Kaneki E, Okugawa K, Yahata H, Kato K, Gα13-mediated LATS1 down-regulation contributes to epithelial-mesenchymal transition in ovarian cancer, FASEB Journal, 33(12):13683-13694., 2019.12. |
| 20. |
Yahata H, Sonoda K, Okugawa K, Yagi H, Ohgami T, Yasunaga M, Onoyama I, Kaneki E, Asanoma K, Kato K., Survey of the desire to have children and engage in sexual activity after trachelectomy among young Japanese women with early-stage cervical cancer., 10.1111/jog.14099. , 45, 11, 2255, 2019.11. |
| 21. |
Kodama K, Sonoda K, Kijima M, Yamaguchi S, Yagi H, Yasunaga M, Ohgami T, Onoyama I, Kaneki E, Okugawa K, Yahata H, Ohishi Y, Oda Y, Kato K., Retrospective analysis of treatment and prognosis for uterine leiomyosarcoma: 10-year experience of a single institute., Asia Pac J Clin Oncol, 10.1111/ajco.13286. , 16, 2, 2019.11. |
| 22. |
Asanoma K, Hori E, Yoshida S, Yagi H, Onoyama I, Kodama K, Yasunaga M, Ohgami T, Kaneki E, Okugawa K, Yahata H, Kato K., Mutual suppression between BHLHE40/BHLHE41 and the MIR301B-MIR130B cluster is involved in epithelial-to-mesenchymal transition of endometrial cancer cells., Oncotarget, 10.18632/oncotarget.27061., 10, 45, 4640, 2019.07. |
| 23. |
Fukami T, Yoshizato T, Miyamoto S, Yagi H, Yotsumoto F, Nabeshima K, Hachisuga T, Kuroki M, Kawarabayashi T., Amphiregulin regulates the production of human chorionic gonadotropin in trophoblasts, 10.1016/j.lfs.2009.03.009. , 84, 23-24, 796, 2019.06. |
| 24. |
Yahata H, Kobayashi H, Sonoda K, Kodama K, Yagi H, Yasunaga M, Ohgami T, Onoyama I, Kaneki E, Okugawa K, Baba S, Isoda T, Ohishi Y, Oda Y, Kato K., Prognostic outcome and complications of sentinel lymph node navigation surgery for early-stage cervical cancer., Int J Clin Oncol, 10.1007/s10147-018-1327-y., 23, 6, 1167, 2018.12. |
| 25. |
Ohmaru-Nakanishi T, Asanoma K, Fujikawa M, Fujita Y, Yagi H, Onoyama I, Hidaka N, Sonoda K, Kato K., Fibrosis in Preeclamptic Placentas Is Associated with Stromal Fibroblasts Activated by the Transforming Growth Factor-β1 Signaling Pathway., Am J Pathol, 10.1016/j.ajpath.2017.11.008., 188, 3, 683, 2018.03. |
| 26. |
Miyata K, Yotsumoto F, Fukagawa S, Kiyoshima C, Ouk NS, Urushiyama D, Ito T, Katsuda T, Kurakazu M, Araki R, Sanui A, Miyahara D, Murata M, Shirota K, Yagi H, Takono T, Kato K, Yaegashi N, Akazawa K, Kuroki M, Yasunaga S, Miyamoto S., Serum Heparin-binding Epidermal Growth Factor-like Growth Factor (HB-EGF) as a Biomarker for Primary Ovarian Cancer, 10.21873/anticanres.11779., 37, 7, 3955, 2017.07. |
| 27. |
Fukagawa S, Miyata K, Yotsumoto F, Kiyoshima C, Nam SO, Anan H, Katsuda T, Miyahara D, Murata M, Yagi H, Shirota K, Yasunaga S, Kato K, Miyamoto S., MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer, Cancer Sci, 10.1111/cas.13210., 108, 5, 886, 2017.05. |
| 28. |
Kitade S, Onoyama I, Kobayashi H, Yagi H, Yoshida S, Kato M, Tsunematsu R, Asanoma K, Sonoda K, Wake N, Hata K, Nakayama KI, Kato K., FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors., Cancer Sci, 10.1111/cas.13026., 107, 10, 1399, 2016.10. |
| 29. |
Yagi H, Asanoma K, Ohgami T, Ichinoe A, Sonoda K, Kato K, GEP oncogene promotes cell proliferation through YAP activation in ovarian cancer, ONCOGENE, 10.1038/onc.2015.505, 35, 34, 4471-4480, 2016.08. |
| 30. |
Asanoma K, Liu G, Yamane T, Miyanari Y, Takao T, Yagi H, Ohgami T, Ichinoe A, Sonoda K, Wake N, Kato K, Regulation of the Mechanism of TWIST1 Transcription by BHLHE40 and BHLHE41 in Cancer Cells, MOLECULAR AND CELLULAR BIOLOGY, 10.1128/MCB.00678-15, 35, 24, 4096-4109, 2015.12. |
| 31. |
Yamane T, Asanoma K, Kobayashi H, Liu G, Yagi H, Ohgami T, Ichinoe A, Sonoda K, Wake N, Kato K., Identification of the Critical Site of Calponin 1 for Suppression of Ovarian Cancer Properties., Anticancer Res, 35, 11, 5993, 2015.11. |
| 32. |
Sonoda K, Yahata H, Ichinoe A, Okugawa K, Kaneki E, Kawano Y, Kenjo H, Ohgami T, Yagi H, Ohga S, Asai K, Nakamura K, Honda H, Kato K., Retrospective Analysis of Concurrent Chemoradiation with Triweekly Cisplatin plus 5-Fluorouracil Versus Weekly Cisplatin in Cervical Cancer., Anticancer Res, 35, 6, 3447, 2015.09. |
| 33. |
Okamoto K, Tsunematsu R, Tahira T, Sonoda K, Asanoma K, Yagi H, Yoneda T, Hayashi K, Wake N, Kato K., SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers, BMC Med Genet, 10.1186/s12881-015-0216-8., 16, 67, 2015.08. |
| 34. |
Nam SO, Yotsumoto F, Miyata K, Suzaki Y, Yagi H, Odawara T, Manabe S, Ishikawa T, Kuroki M, Mekada E, Miyamoto S., Pre-clinical study of BK-UM, a novel inhibitor of HB-EGF, for ovarian cancer therapy., Anticancer Res, 34, 8, 4615, 2014.08. |
| 35. |
Mikelis CM, Palmby TR, Simaan M, Li W, Szabo R, Lyons R, Martin D, Yagi H, Fukuhara S, Chikumi H, Galisteo R, Mukouyama YS, Bugge TH, Gutkind JS., PDZ-RhoGEF and LARG are essential for embryonic development and provide a link between thrombin and LPA receptors and Rho activation., J Biol Chem, 10.1074/jbc.M112.428599., 288, 17, 12232, 2013.04. |
| 36. |
Nojiri T, Yoshizato T, Fukami T, Obama H, Yagi H, Yotsumoto F, Miyamoto S, Clinical significance of amphiregulin and epidermal growth factor in colostrum, ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 10.1007/s00404-012-2365-8, 286, 3, 643-647, 2012.09. |
| 37. |
Miyamoto S, Iwamoto R, Furuya A, Takahashi K, Sasaki Y, Ando H, Yotsumoto F, Yoneda T, Hamaoka M, Yagi H, Murakami T, Hori S, Shitara K, Mekada E.
, A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells.
, Clin Cancer Res, 17(21):6733-41, 21, 6733-41, 2011.11. |
| 38. |
Yagi H, Tan W, Dillenburg-Pilla P, Armando S, Amornphimoltham P, Simaan M, Weigert R, Molinolo AA, Bouvier M, Gutkind JS, A Synthetic Biology Approach Reveals a CXCR4-G(13)-RhoSignaling Axis Driving Transendothelial Migration of Metastatic Breast Cancer Cells, SCIENCE SIGNALING, 10.1126/scisignal.2002221, 4, 191, 2011.09. |
| 39. |
Sosa MS, Lopez-Haber C, Yang C, Wang H, Lemmon MA, Busillo JM, Luo J, Benovic JL, Klein-Szanto A, Yagi H, Gutkind JS, Parsons RE, Kazanietz MG, Identification of the Rac-GEF P-Rex1 as an Essential Mediator of ErbB Signaling in Breast Cancer, MOLECULAR CELL, 10.1016/j.molcel.2010.11.029, 40, 6, 877-892, 2010.12. |
| 40. |
Yotsumoto F, Fukami T, Yagi H, Funakoshi A, Yoshizato T, Kuroki M, Miyamoto S., Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer., Cancer Sci, 10.1111/j.1349-7006.2010.01671.x. , 101, 11, 2351, 2010.11. |
| 41. |
Sakurai A, Gavard J, Annas-Linhares Y, Basile JR, Amornphimoltham P, Palmby TR, Yagi H, Zhang F, Randazzo PA, Li X, Weigert R, Gutkind JS, Semaphorin 3E Initiates Antiangiogenic Signaling through Plexin D1 by Regulating Arf6 and R-Ras, MOLECULAR AND CELLULAR BIOLOGY, 10.1128/MCB.01652-09, 30, 12, 3086-3098, 2010.06. |
| 42. |
Yagi H, Yotsumoto F, Sonoda K, Kuroki M, Mekada E, Miyamoto S, Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer., Int J Cancer, 124, 6, 1429-39, 2009.03. |
| 43. |
Yagi H, Yotsumoto F, Miyamoto S, Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition., Int J Cancer, 0.1158/1535-7163.MCT-08-0417., 7, 10, 3441, 2008.10. |
| 44. |
Yotsumoto F, Yagi H, Suzuki SO, Oki E, Tsujioka H, Hachisuga T, Sonoda K, Kawarabayashi T, Mekada E, Miyamoto S., Validation of hb-egf and amphiregulin as targets for human cancer therapy., Bioche Biophys Res Commun, 10.1016/j.bbrc.2007.11.015., 365, 3, 555, 2008.01. |
| 45. |
Sonoda K, Miyamoto S, Yotsumoto F, Yagi H, Nakashima M, Watanabe T, Nakano H., Clinical significance of RCAS1 as a biomarker of ovarian cancer., Oncol Rep, 17, 3, 623, 2007.05. |
| 46. |
Sonoda K, Miyamoto S, Hirakawa T, Yagi H, Yotsumoto F, Nakashima M, Watanabe T, Nakano H, Clinical significance of RCAS1 as a biomarker of uterine cancer., Gynecol Oncol, 10.1016/j.ygyno.2006.05.047., 103, 3, 924, 2006.12. |
| 47. |
Sonoda K, Miyamoto S, Hirakawa T, Yagi H, Yotsumoto F, Nakashima M, Watanabe T, Nakano H, Invasive potency related to RCAS1 expression in uterine cervical cancer, Gynecol Oncol, 10.1016/j.ygyno.2005.06.061. , 99, 1, 189, 2005.10. |
| 48. |
Tanaka Y, Miyamoto S, Suzuki SO, Oki E, Yagi H, Sonoda K, Yamazaki A, Mizushima H, Maehara Y, Mekada E, Nakano H., Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer., Clin Cancer Res, 10.1158/1078-0432.CCR-04-1426., 11, 13, 4783, 2005.07. |
| 49. |
Sonoda K, Miyamoto S, Hirakawa T, Yagi H, Yotsumoto F, Nakashima M, Watanabe T, Nakano H, Association between RCAS1 expression and microenvironmental immune cell death in uterine cervical cancer., Gynecol Oncol, 10.1016/j.ygyno.2005.02.025., 97, 3, 772, 2005.06. |
| 50. |
Yagi H, Miyamoto S, Tanaka Y, Sonoda K, Kobayashi H, Kishikawa T, Iwamoto R, Mekada E, Nakano H., Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer, Br J Cancer, 10.1038/sj.bjc.6602536., 92, 9, 1737, 2005.05. |
| 51. |
Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, Mizushima H, Tanaka Y, Yagi H, Sonoda K, Kai M, Kanoh H, Nakano H, Mekada E., Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy., Cancer Res, 10.1158/0008-5472.CAN-04-0811., 64, 16, 5720, 2004.08. |
